279 related articles for article (PubMed ID: 16119973)
1. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
Layton D; Wilton LV; Shakir SA
Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
[TBL] [Abstract][Full Text] [Related]
7. Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
Harrison-Woolrych M; Herbison P; McLean R; Ashton J; Slattery J
Drug Saf; 2005; 28(5):435-42. PubMed ID: 15853444
[TBL] [Abstract][Full Text] [Related]
8. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Lee YH; Ji JD; Song GG
Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
[TBL] [Abstract][Full Text] [Related]
9. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
10. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
[TBL] [Abstract][Full Text] [Related]
11. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
13. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
14. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
[TBL] [Abstract][Full Text] [Related]
16. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
Gudbjornsson B; Thorsteinsson SB; Sigvaldason H; Einarsdottir R; Johannsson M; Zoega H; Halldorsson M; Thorgeirsson G
Eur J Clin Pharmacol; 2010 Jun; 66(6):619-25. PubMed ID: 20157701
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
19. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
20. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Lévesque LE; Brophy JM; Zhang B
CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
